PHLDA3 and lung neuroendocrine neoplasm: In summary, it will be worth investigating if PHLDA3, found to be functionally deficient in PanNETs, lung NETs, and rectal NETs, is a TSG for even other subtypes of NETs or wild-type p53 cancers, also in the perspective of targeted therapies.